Pelthos Therapeutics (PTHS) Cash from Operations (2023 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Cash from Operations of 6252000.0 for Q4 2025, down 833.13% year-over-year from 852776.87 in Q4 2024, and up 59.03% quarter-over-quarter from 15258729.0 in Q3 2025.
Pelthos Therapeutics (PTHS) Cash from Operations (2023 - 2026) Analysis & Trends
Pelthos Therapeutics' Cash from Operations history runs 3 years deep, the most recent figure standing at 6252000.0 for Q4 2025.
- In Q4 2025, Cash from Operations fell 833.13% year-over-year to 6252000.0; the TTM figure through Dec 2025 stood at 22590000.0 (down 290.02% YoY), while the FY2025 annual figure was 22590000.0, down 290.02% from the prior year.
- Cash from Operations for Q4 2025 stood at 6252000.0, up from 15258729.0 in the prior quarter.
- The five-year high for Cash from Operations was 173369.0 in Q1 2023, with the low at 15258729.0 in Q3 2025.
- The 3-year median for Cash from Operations is 539635.5 (2025), against an average of 2446919.25.
- Peak annual rise in Cash from Operations reached 84.85% in 2025, while the deepest fall reached 8487.18% in 2025.
- Pelthos Therapeutics' Cash from Operations stood at 356807.0 in 2023, then slumped by 87.78% to 670000.0 in 2024, then tumbled by 833.13% to 6252000.0 in 2025.
- Business Quant data shows PTHS's Cash from Operations at 6252000.0 in Q4 2025, 15258729.0 in Q3 2025, and 447145.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Pelthos Therapeutics | 91.09 Mn | 66.53 Mn | 21.23 Mn | -20.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.79 Mn |
| Jun 30, 2026 | -20.79 Mn |
| Dec 31, 2025 | -6.25 Mn |
| Dec 31, 2025 | -6.25 Mn |
| Sep 30, 2025 | -15.26 Mn |
| Sep 30, 2025 | -15.26 Mn |
| Jun 30, 2025 | -447,145.00 |
| Jun 30, 2025 | -447,145.00 |
| Mar 31, 2025 | -632,126.00 |
| Mar 31, 2025 | -632,126.00 |
| Dec 31, 2024 | -670,000.00 |
| Dec 31, 2024 | -670,000.00 |
| Sep 30, 2024 | -177,692.00 |
| Sep 30, 2024 | -177,692.00 |
| Jun 30, 2024 | -2.95 Mn |
| Jun 30, 2024 | -2.95 Mn |
| Mar 31, 2024 | -1.99 Mn |
| Mar 31, 2024 | -1.99 Mn |
| Dec 31, 2023 | -356,807.00 |
| Dec 31, 2023 | -356,807.00 |